| 113 -1.67 (-1.46%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 168.98  |
1-year : | 192.35 |
| Resists | First : | 144.68 |
Second : | 164.69 |
| Pivot price | 127.5 |
|||
| Supports | First : | 112.3 |
Second : | 93.44 |
| MAs | MA(5) : | 118.31 |
MA(20) : | 133.43 |
| MA(100) : | 164.34 |
MA(250) : | 152.25  |
|
| MACD | MACD : | -10.3 |
Signal : | -9 |
| %K %D | K(14,3) : | 1.3 |
D(3) : | 2.2 |
| RSI | RSI(14): 25 |
|||
| 52-week | High : | 212 | Low : | 92.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IRTC ] has closed above bottom band by 7.1%. Bollinger Bands are 35.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 116.7 - 117.52 | 117.52 - 118.15 |
| Low: | 110.2 - 111.29 | 111.29 - 112.13 |
| Close: | 111.49 - 112.97 | 112.97 - 114.1 |
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Fri, 13 Mar 2026
Evercore ISI Group Maintains iRhythm Technologies (IRTC) In-Line Recommendation - MSN
Thu, 12 Mar 2026
Victory Capital Management Inc. Acquires 18,053 Shares of iRhythm Technologies $IRTC - MarketBeat
Thu, 12 Mar 2026
Mackenzie Financial Corp Sells 274,552 Shares of iRhythm Technologies $IRTC - MarketBeat
Sat, 07 Mar 2026
iRhythm Technologies, Inc. (NASDAQ:IRTC) Q4 2025 earnings call transcript - MSN
Mon, 02 Mar 2026
iRhythm Holdings, Inc. (IRTC) Reports $5.6M Net Income, 70.9% Gross Margin in Q4 2025 - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 32 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 111.5 (%) |
| Shares Short | 3,400 (K) |
| Shares Short P.Month | 2,750 (K) |
| EPS | -1.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.73 |
| Profit Margin | -6 % |
| Operating Margin | 4.1 % |
| Return on Assets (ttm) | -2.4 % |
| Return on Equity (ttm) | -36.6 % |
| Qtrly Rev. Growth | 27.1 % |
| Gross Profit (p.s.) | 16.31 |
| Sales Per Share | 23.11 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 81 (M) |
| Levered Free Cash Flow | 72 (M) |
| PE Ratio | -80.72 |
| PEG Ratio | 0 |
| Price to Book value | 23.89 |
| Price to Sales | 4.88 |
| Price to Cash Flow | 45.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|